{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    21,
    22,
    23,
    24,
    25
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "The primary objective of this study is to compare the change from baseline in HbA1c after 24 weeks of double-blinded treatment with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective 1",
        "text": "Compare the percent change from baseline in total daily insulin dose with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective 2",
        "text": "Compare the percent change from baseline in body weight with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective 3",
        "text": "Compare the change from baseline in the mean value of 24-hour glucose readings obtained from continuous glucose monitoring (CGM) with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective 4",
        "text": "Compare the change from baseline in mean amplitude of glucose excursion (MAGE) of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective 5",
        "text": "Compare the change from baseline in the percent of 24-hour glucose readings obtained from CGM that falls within the target range of >70 mg/dL and <=180 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Efficacy Objective 6",
        "text": "Compare dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin for the proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit >=0.5% without severe hypoglycemia events",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Safety Objective 1",
        "text": "To assess the proportion of subjects with hypoglycemia events and the frequency and severity of the hypoglycemia events with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Safety Objective 2",
        "text": "To evaluate the safety and tolerability by assessment of adverse events (AE), vital signs, diabetic ketoacidosis (DKA) events, physical examination findings, ECG, and laboratory values",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 1",
        "text": "Assess the proportion of subjects with HbA1c reduction of at least 0.5% (>=0.5%) from baseline with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 2",
        "text": "Assess the proportion of subjects with HbA1c < 7.0% with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective 3",
        "text": "Assess the change from baseline in fasting plasma glucose (FPG) with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_13",
        "name": "Exploratory Objective 4",
        "text": "Assess the change from baseline in the percent of 24-hour glucose readings obtained from CGM that is within the hypoglycemic range of <=70 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_14",
        "name": "Exploratory Objective 5",
        "text": "Assess the change from baseline in seated systolic blood pressure with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment among subjects with hypertension at baseline",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_15",
        "name": "Exploratory Objective 6",
        "text": "Assess the change from baseline in average glucose values measured by 6-point self monitored blood glucose (SMBG) with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_16",
        "name": "Exploratory Objective 7",
        "text": "Assess the change from baseline in postprandial glucose values measured by 6-point SMBG with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_16"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_17",
        "name": "Exploratory Objective 8",
        "text": "Assess the change from baseline in postprandial glucose values measured by CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_17"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_18",
        "name": "Exploratory Objective 9",
        "text": "Assess the change from baseline in standard deviation of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_18"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_19",
        "name": "Exploratory Objective 10",
        "text": "Assess the change from baseline to Week 24 in health status, as measured by the Euro Quality of life 5 dimensions 3 levels (EQ-5D-3L) questionnaire",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_19"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_20",
        "name": "Exploratory Objective 11",
        "text": "Assess the changes from baseline to Week 24 in the summary score for treatment satisfaction and scores for perceived frequency of hyperglycemia and perceived frequency of hypoglycemia, respectively, as measured by the Diabetes Treatment Satisfaction Questionnaire status (DTSQs)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_20"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_21",
        "name": "Exploratory Objective 12",
        "text": "Assess the change from baseline to Week 24 in the fear of hypoglycemia as measured by the Hypoglycemia Fear Survey (HFS-II) Worry Subscale score",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_22",
        "name": "Exploratory Objective 13",
        "text": "To explore the relationship between observed and/or model estimated pharmacokinetic measures of exposure (eg, AUCss, Cmax, Cmin) and efficacy and/or safety endpoints by using model-based approaches.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_22"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_23",
        "name": "Exploratory Objective 14",
        "text": "Compare the number of non-severe hypoglycemic events per subject in those achieving an HbA1c reduction of >=0.5% on dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin from baseline to Week 24 visit.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_23"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Change in HbA1c from baseline to Week 24",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint 1",
        "text": "Percent change from baseline to Week 24 in total daily insulin dose",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint 2",
        "text": "Percent change from baseline to Week 24 in total body weight",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint 3",
        "text": "Change from baseline to Week 24 in the mean value of 24-hour glucose readings obtained from CGM",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint 4",
        "text": "Mean amplitude of glucose excursion of 24-hour glucose readings obtained from CGM",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint 5",
        "text": "Percent of 24-hour glucose readings obtained from CGM that fall within the range of > 70 mg/dL and <= 180 mg/dL",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint 6",
        "text": "Proportion of subjects achieving an HbA1c reduction from baseline to Week 24 >=0.5% without severe hypoglycemia events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Safety Endpoint 1",
        "text": "Proportion of subjects with hypoglycemia events and the frequency and severity of the hypoglycemia events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "Secondary Safety Endpoint 2",
        "text": "Adverse events (AE), vital signs, diabetic ketoacidosis (DKA) events, physical examination findings, ECG, and laboratory values",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Endpoint 1",
        "text": "Proportion of subjects with HbA1c reduction of at least 0.5% (>=0.5%) from baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Endpoint 2",
        "text": "Proportion of subjects with HbA1c < 7.0%",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Endpoint 3",
        "text": "Change from baseline in fasting plasma glucose (FPG)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Endpoint 4",
        "text": "Change from baseline in the percent of 24-hour glucose readings obtained from CGM that is within the hypoglycemic range of <=70 mg/dL",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Exploratory Endpoint 5",
        "text": "Change from baseline in seated systolic blood pressure among subjects with hypertension at baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Exploratory Endpoint 6",
        "text": "Change from baseline in average glucose values measured by 6-point SMBG",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_16",
        "name": "Exploratory Endpoint 7",
        "text": "Change from baseline in postprandial glucose values measured by 6-point SMBG",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_17",
        "name": "Exploratory Endpoint 8",
        "text": "Change from baseline in postprandial glucose values measured by CGM",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_18",
        "name": "Exploratory Endpoint 9",
        "text": "Change from baseline in standard deviation of 24-hour glucose readings obtained from CGM",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_19",
        "name": "Exploratory Endpoint 10",
        "text": "Change from baseline to Week 24 in health status, as measured by the Euro Quality of life 5 dimensions 3 levels (EQ-5D-3L) questionnaire",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_20",
        "name": "Exploratory Endpoint 11",
        "text": "Changes from baseline to Week 24 in the summary score for treatment satisfaction and scores for perceived frequency of hyperglycemia and perceived frequency of hypoglycemia (DTSQs)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_21",
        "name": "Exploratory Endpoint 12",
        "text": "Change from baseline to Week 24 in the fear of hypoglycemia as measured by the Hypoglycemia Fear Survey (HFS-II) Worry Subscale score",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_22",
        "name": "Exploratory Endpoint 13",
        "text": "Pharmacokinetic measures of exposure (eg, AUCss, Cmax, Cmin)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_23",
        "name": "Exploratory Endpoint 14",
        "text": "Number of non-severe hypoglycemic events per subject in those achieving an HbA1c reduction of >=0.5%",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand (Primary)",
        "populationSummary": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset) Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Premature discontinuation of randomized treatment",
            "text": "Subject discontinues study medication before Week 24",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Insulin up-titration",
            "text": "Adjustment/increase of background insulin dose",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset)",
        "variableOfInterest": "Change in HbA1c from baseline to Week 24",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_2",
        "name": "ITT Estimand (Secondary)",
        "populationSummary": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset) Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of randomized treatment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Insulin up-titration",
            "text": "Adjustment/increase of background insulin dose",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset)",
        "variableOfInterest": "Change in HbA1c from baseline to Week 24",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Insulin Dose",
        "populationSummary": "Full Analysis Dataset Summary measure: Difference in least squares means (log-transformed).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of randomized treatment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Full Analysis Dataset",
        "variableOfInterest": "Percent change from baseline to Week 24 in total daily insulin dose",
        "summaryMeasure": "Difference in least squares means (log-transformed)"
      },
      {
        "id": "est_4",
        "name": "Secondary Efficacy Estimand - Body Weight",
        "populationSummary": "Full Analysis Dataset Summary measure: Difference in least squares means (log-transformed).",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of randomized treatment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Full Analysis Dataset",
        "variableOfInterest": "Percent change from baseline to Week 24 in total body weight",
        "summaryMeasure": "Difference in least squares means (log-transformed)"
      },
      {
        "id": "est_5",
        "name": "Secondary Efficacy Estimand - Composite Responder",
        "populationSummary": "Full Analysis Dataset Summary measure: Odds ratio (via logistic regression).",
        "analysisPopulationId": "est_5_pop",
        "variableOfInterestId": "ep_7",
        "interventionIds": [
          "est_5_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_7",
            "name": "Severe hypoglycemia event",
            "text": "Occurrence of severe hypoglycemia",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Full Analysis Dataset",
        "variableOfInterest": "Proportion of subjects achieving an HbA1c reduction from baseline to Week 24 >=0.5% without severe hypoglycemia",
        "summaryMeasure": "Odds ratio (via logistic regression)"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 8,
      "exploratoryObjectives": 14,
      "totalEndpoints": 23,
      "totalEstimands": 5
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "The primary objective of this study is to compare the change from baseline in HbA1c after 24 weeks of double-blinded treatment with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective 1",
        "text": "Compare the percent change from baseline in total daily insulin dose with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective 2",
        "text": "Compare the percent change from baseline in body weight with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective 3",
        "text": "Compare the change from baseline in the mean value of 24-hour glucose readings obtained from continuous glucose monitoring (CGM) with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective 4",
        "text": "Compare the change from baseline in mean amplitude of glucose excursion (MAGE) of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective 5",
        "text": "Compare the change from baseline in the percent of 24-hour glucose readings obtained from CGM that falls within the target range of >70 mg/dL and <=180 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Efficacy Objective 6",
        "text": "Compare dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin for the proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit >=0.5% without severe hypoglycemia events",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Safety Objective 1",
        "text": "To assess the proportion of subjects with hypoglycemia events and the frequency and severity of the hypoglycemia events with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Safety Objective 2",
        "text": "To evaluate the safety and tolerability by assessment of adverse events (AE), vital signs, diabetic ketoacidosis (DKA) events, physical examination findings, ECG, and laboratory values",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 1",
        "text": "Assess the proportion of subjects with HbA1c reduction of at least 0.5% (>=0.5%) from baseline with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 2",
        "text": "Assess the proportion of subjects with HbA1c < 7.0% with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective 3",
        "text": "Assess the change from baseline in fasting plasma glucose (FPG) with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_13",
        "name": "Exploratory Objective 4",
        "text": "Assess the change from baseline in the percent of 24-hour glucose readings obtained from CGM that is within the hypoglycemic range of <=70 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_14",
        "name": "Exploratory Objective 5",
        "text": "Assess the change from baseline in seated systolic blood pressure with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment among subjects with hypertension at baseline",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_15",
        "name": "Exploratory Objective 6",
        "text": "Assess the change from baseline in average glucose values measured by 6-point self monitored blood glucose (SMBG) with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_16",
        "name": "Exploratory Objective 7",
        "text": "Assess the change from baseline in postprandial glucose values measured by 6-point SMBG with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_16"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_17",
        "name": "Exploratory Objective 8",
        "text": "Assess the change from baseline in postprandial glucose values measured by CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_17"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_18",
        "name": "Exploratory Objective 9",
        "text": "Assess the change from baseline in standard deviation of 24-hour glucose readings obtained from CGM with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_18"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_19",
        "name": "Exploratory Objective 10",
        "text": "Assess the change from baseline to Week 24 in health status, as measured by the Euro Quality of life 5 dimensions 3 levels (EQ-5D-3L) questionnaire",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_19"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_20",
        "name": "Exploratory Objective 11",
        "text": "Assess the changes from baseline to Week 24 in the summary score for treatment satisfaction and scores for perceived frequency of hyperglycemia and perceived frequency of hypoglycemia, respectively, as measured by the Diabetes Treatment Satisfaction Questionnaire status (DTSQs)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_20"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_21",
        "name": "Exploratory Objective 12",
        "text": "Assess the change from baseline to Week 24 in the fear of hypoglycemia as measured by the Hypoglycemia Fear Survey (HFS-II) Worry Subscale score",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_21"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_22",
        "name": "Exploratory Objective 13",
        "text": "To explore the relationship between observed and/or model estimated pharmacokinetic measures of exposure (eg, AUCss, Cmax, Cmin) and efficacy and/or safety endpoints by using model-based approaches.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_22"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_23",
        "name": "Exploratory Objective 14",
        "text": "Compare the number of non-severe hypoglycemic events per subject in those achieving an HbA1c reduction of >=0.5% on dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin from baseline to Week 24 visit.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_23"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Change in HbA1c from baseline to Week 24",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint 1",
        "text": "Percent change from baseline to Week 24 in total daily insulin dose",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint 2",
        "text": "Percent change from baseline to Week 24 in total body weight",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint 3",
        "text": "Change from baseline to Week 24 in the mean value of 24-hour glucose readings obtained from CGM",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint 4",
        "text": "Mean amplitude of glucose excursion of 24-hour glucose readings obtained from CGM",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint 5",
        "text": "Percent of 24-hour glucose readings obtained from CGM that fall within the range of > 70 mg/dL and <= 180 mg/dL",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint 6",
        "text": "Proportion of subjects achieving an HbA1c reduction from baseline to Week 24 >=0.5% without severe hypoglycemia events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Safety Endpoint 1",
        "text": "Proportion of subjects with hypoglycemia events and the frequency and severity of the hypoglycemia events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "Secondary Safety Endpoint 2",
        "text": "Adverse events (AE), vital signs, diabetic ketoacidosis (DKA) events, physical examination findings, ECG, and laboratory values",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Endpoint 1",
        "text": "Proportion of subjects with HbA1c reduction of at least 0.5% (>=0.5%) from baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Endpoint 2",
        "text": "Proportion of subjects with HbA1c < 7.0%",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Endpoint 3",
        "text": "Change from baseline in fasting plasma glucose (FPG)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Endpoint 4",
        "text": "Change from baseline in the percent of 24-hour glucose readings obtained from CGM that is within the hypoglycemic range of <=70 mg/dL",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Exploratory Endpoint 5",
        "text": "Change from baseline in seated systolic blood pressure among subjects with hypertension at baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Exploratory Endpoint 6",
        "text": "Change from baseline in average glucose values measured by 6-point SMBG",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_16",
        "name": "Exploratory Endpoint 7",
        "text": "Change from baseline in postprandial glucose values measured by 6-point SMBG",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_17",
        "name": "Exploratory Endpoint 8",
        "text": "Change from baseline in postprandial glucose values measured by CGM",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_18",
        "name": "Exploratory Endpoint 9",
        "text": "Change from baseline in standard deviation of 24-hour glucose readings obtained from CGM",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_19",
        "name": "Exploratory Endpoint 10",
        "text": "Change from baseline to Week 24 in health status, as measured by the Euro Quality of life 5 dimensions 3 levels (EQ-5D-3L) questionnaire",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_20",
        "name": "Exploratory Endpoint 11",
        "text": "Changes from baseline to Week 24 in the summary score for treatment satisfaction and scores for perceived frequency of hyperglycemia and perceived frequency of hypoglycemia (DTSQs)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_21",
        "name": "Exploratory Endpoint 12",
        "text": "Change from baseline to Week 24 in the fear of hypoglycemia as measured by the Hypoglycemia Fear Survey (HFS-II) Worry Subscale score",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_22",
        "name": "Exploratory Endpoint 13",
        "text": "Pharmacokinetic measures of exposure (eg, AUCss, Cmax, Cmin)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_23",
        "name": "Exploratory Endpoint 14",
        "text": "Number of non-severe hypoglycemic events per subject in those achieving an HbA1c reduction of >=0.5%",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand (Primary)",
        "populationSummary": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset) Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Premature discontinuation of randomized treatment",
            "text": "Subject discontinues study medication before Week 24",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Insulin up-titration",
            "text": "Adjustment/increase of background insulin dose",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset)",
        "variableOfInterest": "Change in HbA1c from baseline to Week 24",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_2",
        "name": "ITT Estimand (Secondary)",
        "populationSummary": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset) Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of randomized treatment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Insulin up-titration",
            "text": "Adjustment/increase of background insulin dose",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Subjects with Type 1 Diabetes Mellitus and inadequate glycemic control (Full Analysis Dataset)",
        "variableOfInterest": "Change in HbA1c from baseline to Week 24",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Insulin Dose",
        "populationSummary": "Full Analysis Dataset Summary measure: Difference in least squares means (log-transformed).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of randomized treatment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Full Analysis Dataset",
        "variableOfInterest": "Percent change from baseline to Week 24 in total daily insulin dose",
        "summaryMeasure": "Difference in least squares means (log-transformed)"
      },
      {
        "id": "est_4",
        "name": "Secondary Efficacy Estimand - Body Weight",
        "populationSummary": "Full Analysis Dataset Summary measure: Difference in least squares means (log-transformed).",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment discontinuation",
            "text": "Premature discontinuation of randomized treatment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Full Analysis Dataset",
        "variableOfInterest": "Percent change from baseline to Week 24 in total body weight",
        "summaryMeasure": "Difference in least squares means (log-transformed)"
      },
      {
        "id": "est_5",
        "name": "Secondary Efficacy Estimand - Composite Responder",
        "populationSummary": "Full Analysis Dataset Summary measure: Odds ratio (via logistic regression).",
        "analysisPopulationId": "est_5_pop",
        "variableOfInterestId": "ep_7",
        "interventionIds": [
          "est_5_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_7",
            "name": "Severe hypoglycemia event",
            "text": "Occurrence of severe hypoglycemia",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Dapagliflozin 5 mg or 10 mg plus adjustable insulin vs Placebo plus adjustable insulin",
        "analysisPopulation": "Full Analysis Dataset",
        "variableOfInterest": "Proportion of subjects achieving an HbA1c reduction from baseline to Week 24 >=0.5% without severe hypoglycemia",
        "summaryMeasure": "Odds ratio (via logistic regression)"
      }
    ]
  }
}